Active TopicsActive Topics  Display List of Forum MembersMemberlist  CalendarCalendar  Search The ForumSearch  HelpHelp
  RegisterRegister  LoginLogin

Stock Synopsis
 The Equity Desk Forum :Investment Ideas - Creating winning portfolios! :Stock Synopsis
Message Icon Topic: Glaxo Pharma - Right Pill Post Reply Post New Topic
Author Message
nav_1996
Senior Member
Senior Member


Joined: 08/Sep/2006
Online Status: Offline
Posts: 803
Quote nav_1996 Replybullet Topic: Glaxo Pharma - Right Pill
    Posted: 15/Feb/2010 at 6:06pm
Looks like growth is back at Glaxo. This quarter it saw topline grow at 20%.

Advantages of owning Glaxo:
1. It may grow slower that Indian pharma companies but growth will be consistent and profitable.
2. Great balance sheet and 2% div yield.
3. As patent regime sets in they will launch new products from parent which will accelerate top/bottomline growth.
4. It is a great way to own a Pharma stock FMCG way. You don't need to worry about ANDA, DANDA, API and so on.
5. Parent commited to listed entity unlike some other MNCs.

Should be a solid steady compounder. Don't wait for it be very cheap. Has always traded at premium valuations.
IP IP Logged
master
Senior Member
Senior Member
Avatar

Joined: 06/May/2008
Online Status: Offline
Posts: 831
Quote master Replybullet Posted: 16/Feb/2010 at 11:18pm
GSK to increase headcount, introduce more products
 
In a relatively bad year (CY09), it can grow sales at 12%, manage EBIDTA margin at 36% and NPM at 27%. What a business this company has!
 
 
 
 


Edited by master - 16/Feb/2010 at 11:22pm
Someone’s sitting in shade today because someone planted a tree long time ago.
IP IP Logged
beryr
Groupie
Groupie


Joined: 23/Nov/2008
Online Status: Offline
Posts: 45
Quote beryr Replybullet Posted: 18/Feb/2010 at 2:28pm
 Any views on Abbott, Merck , Wyeth too .
IP IP Logged
master
Senior Member
Senior Member
Avatar

Joined: 06/May/2008
Online Status: Offline
Posts: 831
Quote master Replybullet Posted: 22/Feb/2010 at 9:33pm
Few take-away from motilal report on GSK Pharma
  1. Revenue growth by 12% p.a. in next 2 years; focus on generating higher no. of prescriptions rather than price increase.
  2. EBIDTA margins likely to be sustained.
  3. Earnings growth of about 14% (EPS estimate for Dec-11 at Rs 78)
  4. Parent's acquisition of Stiefel Labs globally will strengthen GSK India's presence in dermatology segment.
  5. Rs40 cr capex annually going forward and one time capex of Rs50-60 cr for ramp-up in Nasik facility


Edited by master - 22/Feb/2010 at 9:36pm
Someone’s sitting in shade today because someone planted a tree long time ago.
IP IP Logged
nav_1996
Senior Member
Senior Member


Joined: 08/Sep/2006
Online Status: Offline
Posts: 803
Quote nav_1996 Replybullet Posted: 27/Apr/2010 at 11:47am
Glaxo does it again.

Reports 19% topline and 13% bottomline growth.

Noticeable is topline growth where it is outperforming Indian companies and grabing market share.
IP IP Logged
Post Reply Post New Topic
Printable version Printable version

Forum Jump 		You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot delete your posts in this forum
You cannot edit your posts in this forum
You cannot create polls in this forum
You cannot vote in polls in this forum



This page was generated in 0.094 seconds.
 Bookmark this Page

Partner Site India Forums : Indian Television, Bollywood, Bollywood movies, Discuss TV Shows India, Indian Television Serials Forum, Star Plus, Set India, Zee TV with Daily Update
Powered by